化学信息：
| 化学名 | 1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione |
|
| 简称 | BMS626529 | |
| 别名 |
Temsavir, BMS 626529, BMS-626529 |
|
| 中文名 | N/A | |
| 化学式 | C24H23N7O4 | |
| 分子量 | 473.48 | |
| CAS号 | 701213-36-7 | |
| 纯度 | 98% | |
| 溶剂/溶解度 |
Water<1mg/ml; DMSO5mg/ml; Ethanol<1mg/ml |
|
| 溶液配制 | 5mg加入1.06ml DMSO，或者每4.73mg加入1ml DMSO，配制成10mM溶液。SC3301-10mM用DMSO配制。 |
生物信息：
| 产品描述 | BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells. | ||||
| 信号通路 | Anti-infection | ||||
| 靶点 | HIV | － | － | － | － |
| IC50 | － | － | － | － | － |
| 体外研究 | BMS-626529 is a member of the new drug class of HIV-1 attachment inhibitors currently in development. BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529, a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells. The activity of BMS-626529 is virus dependent, due to heterogeneity within gp120. Research result suggest that BMS-626529 should be active against the majority of HIV-1 viruses and support the continued clinical development of the compound. | ||||
| 体内研究 | N/A | ||||
| 临床实验 | N/A | ||||
| 特征 | N/A | ||||
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
| 酶活性检测实验 | |
| 方法 | N/A |
| 细胞实验 | |
| 细胞系 | N/A |
| 浓度 | N/A |
| 处理时间 | N/A |
| 方法 | N/A |
| 动物实验 | |
| 动物模型 | N/A |
| 配制 | N/A |
| 剂量 | N/A |
| 给药方式 | N/A |
| 产品编号 | 产品名称 | 包装 |
| SC3301-10mM | BMS626529 (HIV抑制剂) | 10mM×0.2ml |
| SC3301-5mg | BMS626529 (HIV抑制剂) | 5mg |
| SC3301-25mg | BMS626529 (HIV抑制剂) | 25mg |
| — | 说明书 | 1份 |
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
